ThromboGenics Announces Business Update and 2008 Full Year Results

LEUVEN, Belgium - ThromboGenics Reports Pre-Tax Profit of EUR12.2 Million For 2008

ThromboGenics NV (Euronext Brussels: THR), a biotechnology
company focused on the discovery and development of innovative treatments
that will make a real difference to patient care in a number of important
therapeutic areas, is today issuing a business update and its financial
results for the full year ending December 31, 2008.

Chiquita Announces Attendance at the Second Jefferies Consumer Summit and Provides Updated Investor Presentation

CINCINNATI - Chiquita Brands International, Inc. (NYSE: CQB) today announced that
Fernando Aguirre, chief executive officer, and Jeffrey M. Zalla, chief
financial officer, will participate in the Second Jefferies Consumer Summit
on Wednesday, March 18, 2009 in New York City.